P-0071 Sorafenib Versus Oral Fluoropyrimidines in the Management of Advanced Hepatocellular Carcinoma
نویسندگان
چکیده
منابع مشابه
Sorafenib in advanced hepatocellular carcinoma.
BACKGROUND No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS In this multicenter, phase 3, double-blind, placebo-control...
متن کاملSorafenib Effectiveness in Advanced Hepatocellular Carcinoma
BACKGROUND Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Because of narrow trial eligibility, results may not be generalizable to a broader HCC population. We sought to evaluate the effectiveness of initial sorafenib versus no treatment among Medicare beneficiaries with advanced HCC. MATERIALS AND METHODS Patients with advanced HCC diagnosed fro...
متن کاملEfficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
BACKGROUND Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC), its therapeutic benefit is marginal. Here, we aimed to compare the efficacy and safety of sorafenib monotherapy (S-M) and sorafenib-based loco-regional treatments (S-LRTs) in advanced HCC. METHODS From 2007 to 2012, 290 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C...
متن کاملEvolving role of Sorafenib in the management of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide and comes third in cancer-related mortality. Although there is a broad spectrum of treatment options to choose from, only a few patients are eligible candidates to receive a curative therapy according to their stage of disease, and thus palliative treatment is implemented in the majority of the patients suffer...
متن کاملSorafenib in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fi fth most common malignancy worldwide with approximately 500,000 new cases per year, ranking as the third cause of cancer deaths. Until the very recent past no systemic therapy was available for patients with advanced HCC. However, advances achieved in the understanding of the molecular cancer biology and the subsequent introduction of molecularly targete...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2012
ISSN: 0923-7534
DOI: 10.1016/s0923-7534(20)30278-7